Abstract
Direct administration of drugs and genes to the lungs by pulmonary delivery offers a potential effective therapy for lung cancers. In this study, combined doxorubicin (DOX) and Bcl2 siRNA was employed for cancer therapy using polyethylenimine (PEI) as the carrier of Bcl2 siRNA. Most of the DOX and siRNA possessed high cellular uptake efficiency in B16F10 cells, which was proved by FCM and CLSM analysis. Real-time PCR showed that PEI/Bcl2 siRNA exhibited high gene silencing efficiency with 70% Bcl2 mRNA being knocked down. The combination of DOX and siRNA could enhance the cell proliferation inhibition and the cell apoptosis against B16F10 cells compared to free DOX or PEI/Bcl2 siRNA. Furthermore, the biodistribution of DOX and siRNA via pulmonary administration was studied in mice with B16F10 metastatic lung cancer. The results showed that most of the DOX and siRNA were accumulated in lungs and lasted at least for 3 days, which suggested that combined DOX and siRNA by pulmonary administration may have high anti-tumor effects for metastatic lung cancer treatment in vivo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
